TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06495554

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Measurement of circulating tumor-DNA
Description: Liquid biopsies will be collected at baseline and prospectively during follow-up to measure circulating tumor-DNA.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collection of patient-reported outcomes
Description: Patient-reported outcomes will be collected at baseline and prospectively during follow-up.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Algorithmically determined telephone interview with a nurse
Description: Dependent on the patient's responses on the patient-reported outcome measures.
Study: NCT05228015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IK-930
Description: tablets for oral administration
Study: NCT06643455

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05568355

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GET2HOME Intervention
Description: Intervention bundle designed to improve discharge effectiveness
Study: NCT05228015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IK-930
Description: tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IK-930
Description: tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: tablets for oral administration
Study: NCT02616302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole
Description: Dexlansoprazole 15 mg, 30 mg, and 60 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole
Description: Dexlansoprazole 15 mg, 30 mg, and 60 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole
Description: Dexlansoprazole 15 mg, 30 mg, and 60 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole
Description: Dexlansoprazole 15 mg, 30 mg, and 60 mg capsules
Study: NCT05243290

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinamide Riboside
Description: The product under investigation, Nicotinamide riboside (NR), is a naturally occurring NAD+ precursor and a member of the vitamin B3 family.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Visually matching placebo capsules will contain the same inactive ingredients present in the manufactured NR capsules, with the exception of any NR compound.
Study: NCT04740918

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab Emtansine
Description: Trastuzumab emtansine 3.6 mg/kg IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Emtansine
Description: Trastuzumab emtansine 3.6 mg/kg IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg IV infusion
Study: NCT04516967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag
Description: Oral avatrombopag tablet or sprinkle capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag
Description: Oral avatrombopag tablet or sprinkle capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator tablet or sprinkle capsule
Study: NCT05894577

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
Study: NCT04740918

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo matched to atezolizumab
Study: NCT05611177

Intervention type: OTHER
Intervention: machine learning analysis
Description: We will use robust machine learning approaches, such as Random Forest, XGBoost or Neural Networks.

Intervention type: OTHER
Intervention: machine learning analysis
Description: We will use robust machine learning approaches, such as Random Forest, XGBoost or Neural Networks.

Intervention type: OTHER
Intervention: machine learning analysis
Description: We will use robust machine learning approaches, such as Random Forest, XGBoost or Neural Networks.
Study: NCT06064526

Intervention type: OTHER
Intervention: No intervention
Description: Non-interventional study based on secondary use of hospital medical records
Study: NCT06029712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heart failure polypill
Description: Copackaging of heart failure medications (beta blocker, SGLT2i, MRA, and ACE/ARB/ARNI) in an overencapsulated polypill. Individual tablets will be hand-packed into a single capsule at the level of the pharmacy. Specific medications and doses will be individualized to the participant.
Study: NCT06101329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenacapavir Tablet
Description: Tablets administered orally without regard of food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenacapavir Injection
Description: Injection administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF)
Description: 200/300mg fixed dose combination (FDC) tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF)
Description: 200/300mg fixed dose combination (FDC) tablets administered orally
Study: NCT06413134

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TheraPAP
Description: TheraPAP is a novel CPAP-based therapy in which pressure is dropped as much as 5 cmH2O starting at the beginning of inspiration and extending through the end of expiration where it rises back up to the true therapy pressure for a short period. It improves comfort by providing pressure only when it is needed and maintaining it at a low level the rest of the time. Normal CPAP/APAP therapy keeps pressure at the therapy level during the entire breath cycle, except with some alternate approaches where pressure is decreased but only during the expiratory phase.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: APAP
Description: Standard CPAP therapy where therapy pressure is automatically adjusted to prevent respiratory events from occurring. The TheraPAP prototype device will be used to operate in the APAP mode in addition to the TheraPAP intervention mode.
Study: NCT06029712

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control Rx
Description: GDMT delivered as individual tablets
Study: NCT05503134

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Universal Donor Natural Killer Cells
Description: Six doses of UD-NK cells will be given thrice weekly for two weeks for up to 2 cycles of treatment
Study: NCT05792722

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Prostate capsule-sparing radical cystectomy
Description: Patients randomized to this arm will receive the prostate capsule-sparing surgery performed in the form of standard simple prostatectomy. Patients will also have a cystectomy with one of the following urinary diversions: ileal conduit, Indiana Pouch, or orthotopic neobladder.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Nerve sparing radical cystectomy
Description: Patients randomized to this arm will receive the nerve-sparing surgery will be performed in the form of the standard nerve-sparing radical prostatectomy. Patients will also have a cystectomy with one of the following urinary diversions: ileal conduit, Indiana Pouch, or orthotopic neobladder.
Study: NCT05556187

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized automated oxygen titration
Description: Automated oxygen titration based on the oxygen saturation during the entire day.
Study: NCT06630676

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Brief 4-slide presentation without a separate session for questions and answers

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Patients will review 27 slides that discuss the different etiologies (causes) of back pain, how common they are, what causes them (e.g., wear and tear, trauma), factors that exacerbate and alleviate the pain, how they are diagnosed and treated, and have an opportunity to ask questions.
Study: NCT06053411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac
Description: 25 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac
Description: 25 mg capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: curcumin
Description: 2,000 mg tablet
Study: NCT05241834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOXO-260
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOXO-260
Description: Oral
Study: NCT05886881

Intervention type: DEVICE
Intervention: Lotrafilcon B spherical soft contact lenses
Description: Commercially available silicone hydrogel contact lenses

Intervention type: DEVICE
Intervention: Lotrafilcon B spherical soft contact lenses with comfort additive
Description: Commercially available silicone hydrogel contact lenses

Intervention type: DEVICE
Intervention: Lotrafilcon B toric soft contact lenses with comfort additive
Description: Commercially available silicone hydrogel contact lenses

Intervention type: DEVICE
Intervention: Comfilcon A spherical soft contact lenses
Description: Commercially available silicone hydrogel contact lenses

Intervention type: DEVICE
Intervention: Comfilcon A toric soft contact lenses
Description: Commercially available silicone hydrogel contact lenses
Study: NCT05029882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-400
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-400
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-400
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-400
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-400
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-400
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-400
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-400
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-400
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-400
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-400
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine/Tipiracil
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: IV Infusion
Study: NCT04951453

Intervention type: OTHER
Intervention: None (observational)
Description: None (observational)

Intervention type: OTHER
Intervention: None (observational)
Description: None (observational)

Intervention type: OTHER
Intervention: None (observational)
Description: None (observational)
Study: NCT05624957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine epinephrine
Description: Under aseptic condition every one litre of fluid irrigation will be mixture with 10 ml of lidocaine 2% and 0.25mg epinephrine and the last one use before end of surgery dexamethasone 8 mg will be added.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Epinephrin
Description: 0.25 mg epinephrine mixed with one litre of fluid irrigation
Study: NCT06218784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iN1011-N17 HCl Suspension (Part 1)
Description: Dose: 100 mg b.i.d for 7 days (Multiple Ascending Dose)
Study: NCT05020184

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cimetidine
Description: Oral Cimetidine 800mg twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice daily
Study: NCT06218784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iN1011-N17 HCl Capsule (Part 1)
Description: Dose: 200, 400, 800 mg b.i.d for 7 days (Multiple Ascending Dose)
Study: NCT06240507

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound-guided posterior tibial nerve pulsed radiofrequency
Description: The posterior tibial nerve (PTN) was identified with a 5-12 MHz linear ultrasonography (US) probe at the level of the medial malleolus, where it runs posterior to the posterior tibial artery. Using the in-plane technique, a 22-gauge, 10-cm radiofrequency cannula was inserted under US guidance and advanced until the tip was adjacent to the nerve. Pulse radiofrequency was applied at 42°C for 240 s with a pulse width of 20 ms

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fluoroscopy-guided intralesional radiofrequency thermocoagulation
Description: The painful heel and calcaneal spur were visualized under lateral fluoroscopy. A 22-gauge, 10-cm radiofrequency cannula was inserted and advanced until the needle tip reached the calcaneal spur tip. When the needle tip contacted the spur, local anesthetic was administered through the cannula and radiofrequency ablation was performed at 80°C for 90 s.
Study: NCT05894577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Montelukast sodium is a white to off-white powder. The 10 mg montelukast tablets are beige, rounded square-shaped, biconvex, film-coated tablets. Each tablet contains 10.4 mg of montelukast sodium, which is equivalent to 10 mg montelukast. All packaging will be labeled to indicate that the product is for investigational use.
Study: NCT06511011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified Suan ZaoRen Tang-TianWang BuXin Dan
Description: Chinese medicine granules for 6 weeks
Study: NCT04064424

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prevention video advertisement
Description: Skin Cancer Prevention videos

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prevention images for advertisement
Description: Skin Cancer Prevention images

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Advertisement
Description: No skin cancer prevention videos or images were advertised.
Study: NCT06289647

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: In study communities randomized to the Azithromycin Continuation arm, all individuals aged 1 month and older will receive a single mass distribution of azithromycin several weeks after the baseline and 36-month monitoring visits. In study communities randomized to Azithromycin Discontinuation, participants will receive no treatment.
Study: NCT04145635

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aortix System
Description: Aortix is a circulatory support device for chronic heart failure patients on medical management who have been hospitalized for acute decompensated heart failure (ADHF) with worsening renal function.
Study: NCT06218784

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule (Part 1)
Description: Dose: b.i.d for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iN1011-N17 HCl Capsule (Part 2)
Description: Dose: 400 mg QD
Study: NCT05206422

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Doraya Catheter
Description: The Doraya Catheter is a temporary intravenous flow regulator, positioned in the inferior vena cava below the level of the renal veins
Study: NCT06218784

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iN1011-N17 Mesylate Capsule (Part 2)
Description: Dose: 400 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iN1011-N17 HCl Capsule (Part 3)
Description: Dose: 400 mg b.i.d for 14 days
Study: NCT05464329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Description: Provided by Genentech.
Study: NCT05107778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC42 10mg
Description: ASC42 10mg orally once daily;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC42 15mg
Description: ASC42 15mg orally once daily.
Study: NCT05107778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ih PEG-IFN α-2a
Description: ih PEG-IFN α-2a 180μg subcutaneous injection once a week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ih PEG-IFN α-2a
Description: ih PEG-IFN α-2a 180μg subcutaneous injection once a week.
Study: NCT05464329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHAX
Description: -Standard of care. Flexibility in administration is permitted at the discretion of the treating physician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICE
Description: -Standard of care. Flexibility in administration is permitted at the discretion of the treating physician.
Study: NCT05107778

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ih PEG-IFN α-2a
Description: ih PEG-IFN α-2a 180μg subcutaneous injection once a week.
Study: NCT06511011

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo granules for 6 weeks
Study: NCT05308095

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled hypoglycaemic state while driving
Description: Participants will drive on a designated circuit with a real car on a test track accompanied by a driving instructor. Initially, a euglycaemic state (5.0 - 8.0 mmol/L) is established and blood glucose is then declined to hypoglycaemia (3.0 - 3.5 mmol/L) by administering insulin. Thereafter, blood glucose is raised again to euglycaemia (5.0 - 8.0mmol/L). During the procedure, driving data is recorded. Additionally, eye movement, head pose, facial expression, heart rate, skin conductance, and CGM values are recorded throughout the glycemic trajectory. Participants are blinded to the blood glucose values during the procedure.
Study: NCT04651777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI
Description: The investigational drug is a single Ellipta inhaler containing 200 ug fluticasone furoate, 62.5 ug umedlidinium and 25 ug vilanterol. The drug is delivered in an Ellipta inhaler in a single dose once daily.
Study: NCT04096937

Intervention type: OTHER
Intervention: Focus groups
Description: Focus groups will be conducted with adult stakeholders and with youth in Appalachia. Feedback from the focus groups will guide cultural tailoring of the Journey of Hope in Appalachia intervention for use in a later phase.

Intervention type: OTHER
Intervention: Focus groups
Description: Focus groups will be conducted with adult stakeholders and with youth in Appalachia. Feedback from the focus groups will guide cultural tailoring of the Journey of Hope in Appalachia intervention for use in a later phase.
Study: NCT06319898

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lavender aromatherapy sticker
Description: Lavender aromatherapy during procedure, music and dim lighting
Study: NCT06330844

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Race Based Stress and Empowerment Focused Compensatory Cognitive Training for Mild Cognitive Impairment (RBSEF-CCT-MCI)
Description: RBSEF-CCT-MCI differs from ME-CCT in that this intervention integrates psychoeducation and strategies for processing and coping with race/ethnicity-related stressors, as part of the larger conversation in ME-CCT regarding stress, and how stress interferes with attention, learning, and subsequently one's subjective sense of memory.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Motivationally Enhanced Compensatory Cognitive Training for Mild Cognitive Impairment (ME-CCT)
Description: ME-CCT focuses on:~1. Cognitive training, psychotherapeutic, and lifestyle techniques.~2. Incorporates CCT techniques designed to help patients manage problems with memory, attention, and executive functions (i.e., organization, planning, decision-making, and problem-solving).~3. Includes mindfulness-based stress reduction practice which has been shown to improve cognitive and neuropsychiatric function in various populations.
Study: NCT04812678

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fasciatherapy
Description: Fasciatherapy, with manual therapy and/or gestual therapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fasciatherapy
Description: Fasciatherapy, with manual therapy and/or gestual therapy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Conventional physiotherapy with massage, exercises, electrotherapy, vertebral traction, heat, cold.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Conventional physiotherapy with massage, exercises, electrotherapy, vertebral traction, heat, cold.
Study: NCT06218784

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: iN1011-N17 Mesylate Capsule (Part 3)
Description: Dose: 400 mg b.i.d for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Capsule (Part 3)
Description: Dose: b.i.d for 14 days
Study: NCT06425731

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting
Description: Participants (Dance for PD, in-person only) will engage in one of their routine weekly dance sessions while a portable indirect calorimeter is used for energy expenditure analysis. Before this session, participants will be asked to fast for at least 4-hours. In this way, participants in this study arm will engage in a self-controlled study design wherein they complete a 4-hour fast before engaging in an oxygen uptake assessment during their routine dance classes. During the 4-hour fasting period, participants will be asked to refrain from eating any food and drinking any beverages except for water.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Intervention
Description: No Intervention
Study: NCT05517785

Intervention type: OTHER
Intervention: Motor performance tests
Description: Performance of 5 motor tests: plank, single leg stance test, standing long jump test (broad jump), 4 x 10 agility test and 20 m shuttle run tests (beeps), after taking ADHD drug or not taking the drug before motor tests performance

Intervention type: OTHER
Intervention: Motor performance tests
Description: Performance of 5 motor tests: plank, single leg stance test, standing long jump test (broad jump), 4 x 10 agility test and 20 m shuttle run tests (beeps), after taking ADHD drug or not taking the drug before motor tests performance